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The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated
atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity
on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the
polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant
3-fold risk (odds ratio (OR) 2.95; 95% confidence interval (CI) 1.81–4.81, Po0.001) and the Leu7Pro polymorphism–obesity
interaction, with a remarkable 12-fold risk (OR 12.33; 95% CI 1.18–128.35, Po0.05). The Leu7Pro polymorphism modified
significantly the 10-year incidence of cardiovascular events, causing a 7.6-fold increase in the hazard ratio (HR 7.58; 95% CI
2.87–20.03, Po0.001) in the obese but not in the nonobese subjects. The results indicate that obesity may be a pivotal factor in
multiplying the disease risk associated with the Leu7Pro polymorphism in preproNPY.
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Introduction and methods
Several single nucleotide polymorphisms (SNPs) have been
found in the NPY gene (GenBank accession no. NT007819).
The SNP NPY 1228 T4C (rs16139) leading to an amino-acid
chance leucine7 to proline7 (Leu7Pro) in the signal peptide
of NPY is relatively common in European populations; about
7–12% of subjects have the minor Pro7 allele in a hetero-
zygous (Leu7Pro7) or, very rarely, homozygous (Pro7Pro7)
genotype (Karvonen et al., 1998; Ding, 2003). The Pro7 allele
has been associated with increased blood pressure, acceler-
ated atherosclerosis and type II diabetes (Karvonen et al.,
2001; Nordman et al., 2005; Ukkola and Kesaniemi, 2007).
Since obesity is a major risk factor for diabetes and
cardiovascular diseases, among other comorbidities (Poirier
et al., 2006), and the effect of interaction obesity on
genotype has not been well appreciated in all SNP associa-
tion studies, we wanted to evaluate the impact of the
interaction of obesity with the Leu7Pro polymorphism of
preproNPY on blood pressure elevation, cardiovascular
events and abnormal glucose regulation in elderly people.
The study subjects are part of the Hoorn Study, a
population-based cohort study of glucose metabolism and
cardiovascular complications. The cohort has been described
in detail elsewhere (Mooy et al., 1995). The ethical committee
of the VU University Medical Centre approved the study and
written informed consent was received from all study
subjects. A total of 111 obese (body mass index
(BMI)X28 kg m2, mean age 68.1±7.7 years) and 282
nonobese (BMIo28 kg m2, mean age 67.1±7.3 years)
subjects of the total cohort were genotyped for the Leu7Pro
polymorphism of preproNPY as described earlier (Karvonen
et al., 1998).
The study design of the present follow-up study is shown
in Figure 1. The frequency of the Leu7Pro7 genotype was
7.6% (30 out of 393 subjects) and none of the subjects had
the Pro7Pro7 genotype. There was no statistically significant
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difference in frequency of the Leu7Pro7 genotype between
obese and lean subjects (9.0 and 7.1%, respectively;
P¼0.519, w2-test). Multiple linear regression analyses were
performed to investigate simultaneously the associations of
the Leu7Pro7 genotype, obesity and genotype–obesity inter-
action (explanatory variables) with BMI, body weight, waist
to hip ratio, waist and hip circumferences, blood pressure,
glucose metabolism, lipid concentrations and with a change
in these parameters in 6 years (outcome variables). For
investigating simultaneously the effects of the Leu7Pro7
genotype, obesity and genotype–obesity interaction on the
risk for abnormal glucose regulation (impaired fasting
glucose, impaired glucose tolerance and diabetes mellitus)
in 6 years follow-up period, a logistic regression model was
used. The Cox’s proportional hazard model was used to
compare cardiovascular survival in 10 years (fatal or nonfatal
events: angina pectoris, myocardial infarction, congestive
heart failure, stroke, transient ischaemic attack, peripheral
vascular disease and sudden death). All the statistical
analyses were performed using SPSS for Windows (version
12.0.1, SPSS Inc., Chicago, IL, USA).
Results and discussion
After a follow-up of 6 years, all (100%) obese subjects with
the Leu7Pro7 genotype (10 out of 10 subjects) had abnormal
glucose regulation compared to 63.4% (64 out of 101
subjects) of obese subjects with the Leu7Leu7 genotype
(P¼0.019, pcorr¼0.046). In nonobese subjects, 4 out of 20
subjects (20.0%) with the Leu7Pro7 genotype and 107 out
of 262 subjects (40.8%) with the Leu7Leu7 genotype had
developed abnormal glucose regulation (P¼0.066,
pcorr¼0.109). The analysis indicated that obesity caused a
3-fold risk (odds ratio (OR) 2.95, confidence interval (CI)
1.81–4.81, Po0.001) and the Leu7Pro7genotype–obesity
interaction caused a 12-fold risk for incident abnormal
glucose regulation (OR 12.33, CI 1.18–128.35, Po0.05) when
adjusted for age, gender and follow-up time in days. No
effects of genotype or genotype–obesity interaction on lipid
concentrations were detected.
There was a significant positive Leu7Pro7 genotype–
obesity interaction effect on the change in systolic
(P¼0.002) and pulse pressure (P¼0.005) during the 6 years
follow-up (adjusted for age, gender, glucose tolerance status
at baseline, the duration of follow-up in days and the use of
antihypertensive agents). In obese subjects with the Leu7-
Pro7 genotype, the mean increase was 27±20 (s.d.) mm Hg
in systolic blood pressure and 22±16 mm Hg in pulse
pressure; in obese subjects with the Leu7Leu7 genotype,
the increase was 10±17 mm Hg in systolic blood pressure
and 10±15 mm Hg in pulse pressure. A significant positive
Leu7Pro7 genotype–obesity interaction effect was also found
with current systolic blood pressure (P¼0.034) after 6 years
(adjusted for age, gender, glucose tolerance status and the
use of antihypertensive agents). On the contrary, the
Leu7Pro7 genotype alone had a negative association with
current systolic (P¼ 0.004) and diastolic blood pressure
(P¼0.009) after 6 years. There was a significant positive
genotype–obesity interaction effect on 6-year change in BMI
(P¼0.030) and weight (P¼0.033) when adjusted for age,
gender and follow-up time in days. At this time point, the
Leu7Pro7 genotype–obesity interaction was positively asso-
ciated with current body weight (P¼0.046) and waist
circumference (P¼0.048, adjusted for age and gender).
Obese subjects with the Leu7Pro7 genotype had over seven
times higher incidence of cardiovascular events compared to
obese subjects without the Pro7 allele (Table 1). During a 10
years follow-up, 83.3% (5 out of 6 subjects) of obese subjects
with the Leu7Pro7 genotype had a cardiovascular event,
whereas only 39.3% (35 out of 89) of of obese subjects
with the Leu7Leu7 genotype has a cardiovascular event
(P¼0.039, pcorr¼0.092). In the nonobese subjects, there was
no difference in the incidence of cardiovascular events
between the genotypes during the 10 years follow-up
(20.0% in subjects with Leu7Pro7 genotype (3 out of 15
subjects) and 26.5% in subjects with Leu7Leu7 genotype (63
out of 238 subjects, P¼0.580, pcorr¼0.802)).
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Figure 1 Schematic presentation of the study design. Oral glucose tolerance tests (OGTT) and clinical and laboratory measurements were
performed during 6-year intervals. The follow-up for cardiovascular events (CVD) continued for 10 years.
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In the current study, we found in a relatively small cohort
that there is a significant effect of interaction of the
Leu7Pro7 genotype of preproNPY and obesity on the increase
in blood pressure as well as on the risk for abnormal glucose
regulation. We also found that this genotype markedly
increased the incidence of cardiovascular events in obese
but not in nonobese subjects. The results suggest that obesity
may be a pivotal factor directing or multiplying the effect of
Leu7Pro7 genotype on disease risk and should be evaluated
in obesity-related diseases. The mechanisms may involve
increased abdominal obesity among the obese, as found in
this and earlier studies (Ding, 2003), and/or dysregulation of
autonomic and endocrine functions since subjects with the
Leu7Pro7 genotype are prone to harmful autonomic cardio-
vascular changes in response to sympathetic activation
(Kallio et al., 2003; Jaakkola et al., 2005). Furthermore,
another polymorphism in the NPY gene, which may be in
linkage disequilibrium with the Leu7Pro polymorphism, for
example, the NPY399 T4C (rs16147) that regulates
transcription (Buckland et al., 2004), may have a role in
the observed clinical findings.
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Table 1 The hazard ratios (HR) for cardiovascular events (CVD)
according to genotype and obesity status combinations, adjusted for
age, gender, baseline body mass index (BMI), fasting glucose at baseline
and hypertension
preproNPY genotype and obesity status CVD HR (95% CI)
Leu7Leu7 genotype (obese) 1.0 (Reference category)
Leu7Pro7 genotype (obese) 7.58 (2.87–20.03)a
Leu7Leu7 genotype (nonobese) 1.40 (0.74–2.65)
Leu7Pro7 genotype (nonobese) 0.87 (0.24–3.15)
aPo0.001.
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